Which genetic mutations and cytogenetic changes have a more favorable response to MDS treatment?
Learn more about MDS at http://www.YouAndMDS.com
Prof. Valeria Santini, an expert on MDS from the University of Florence, discusses what we currently know about genetic mutations and cytogenetic changes associated with better myelodysplastic syndromes (MDS) treatment outcomes. For example, changes in chromosome 5 (some 5q deletions) can indicate a favorable response to treatment with lenalidomide. A mutation in the gene SF3B1 can also indicate a good prognosis. Prof. Santini discusses the need for transfusion and the role of multiple mutations.
Watch video Which genetic mutations and cytogenetic changes have a more favorable response to MDS treatment? online without registration, duration hours minute second in high quality. This video was added by user You and MDS 27 June 2022, don't forget to share it with your friends and acquaintances, it has been viewed on our site 24 once and liked it people.